<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        40-222-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        UVAMIN 100MG RETARD CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NITROFURANTOIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACINO PHARMA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">UvaminTM 100 mg retard capsules contain 100 mg of nitrofurantoin. Nitrofurantoin is an antibacterial agent. UvaminTM 100 mg retard capsules are used for acute and chronic urinary tract disorders caused by nitrofurantoin-sensitive organisms (e.g. cystitis, infections of the renal pelvis). It may also be used to prevent infections during examinations (e.g. cystoscopy) or after urinary tract surgery. UvaminTM 100 mg retard must be used on medical prescription only.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">a. Do not take Uvamin&trade;&nbsp;<br />&nbsp;<br />Do not take UvaminTM 100 mg retard: - if you have a disease of the kidneys which is severely affecting the way they work (ask your doctor if you are not sure), &nbsp;- if you have little or no urine output, &nbsp;<br />- if you have a nervous system disease such as peripheral neuropathy (polyneuropathy) or inflammation of a peripheral nerve or nerve in the brain (neuritis), &nbsp;- if you have a rare hereditary red blood cell disease known as &ldquo;glucose-6-phosphate dehydrogenase deficiency&rdquo;, &nbsp;- a specific lung disease (pulmonary fibrosis), &nbsp;- if you have a disorder affecting the production of the red pigment in blood (acute porphyria), - if you have a known allergy to nitrofurantoin or to any of the other ingredients of this medicine (listed in Section &ldquo;6. Further information&rdquo;). The manifestations of such hypersensitivity include, for example, asthma, shortness of breath, circulatory disorders, swellings of the skin (e.g. nettle rash) and mucous membranes or skin rashes. - if you are in the final stages of pregnancy (labour or delivery) as there is a risk that it might affect the baby, - if your child under three months of age, - if you are breast feeding a baby with suspected or known deficiency in an enzyme called G6PD (glucose-6-phosphate dehydrogenase). UvaminTM 100 mg retard capsules are not recommended for use in children below 12 years.&nbsp;<br />&nbsp;<br />b. Take special care with Talk to your doctor before taking UvaminTM 100 mg retard if any of the side effects listed below (see &ldquo;4. Possible side effects&rdquo;) have occurred during previous treatment with nitrofurantoin (the active substance in UvaminTM 100 mg retard). In particular, liver and skin symptoms must be mentioned. You must inform your doctor if you have any problems with your kidneys, if you suffer from any disease of the lungs, liver or nervous system, if you have anaemia (a decrease in red blood cells causing pale skin, weakness and breathlessness), diabetes, motor weakness or vitamin B deficiency. If you need to take UvaminTM 100 mg retard for a number of months, your doctor may want to regularly check how your lungs and liver are working. Tell your doctor if you lack an enzyme (body chemical) called glucose-6-phosphate dehydrogenase, which causes your red blood cells to be more easily damaged.&nbsp;<br />&nbsp;<br />c. Taking other medicines Your doctor must be informed if you are taking certain medicines for infections, e.g. those containing the active substance nalidixic acid, medicines that increase uric acid excretion (antigout medicines) containing the active substances sulphinpyrazone or probenecid, medicines containing the active substance phenytoin, used to treat convulsive disorders (epilepsy) or medicines containing propantheline, used to block stomach acid secretion. As co-administration of certain antacids (medicines used to treat excess stomach acid) reduces nitrofurantoin absorption, nitrofurantoin must be administered at least one hour before the&nbsp;antacids. Tell your doctor or pharmacist if you are taking, have recently taken or might take typhoid vaccine, which is given for the prevention of typhoid. Nitrofurantoin blocks the antibacterial action of certain other medicines used to treat urinary tract infections. As with other antibiotics, nitrofurantoin can compromise the intestinal flora, which leads to reduced effectiveness of certain contraceptives. Additional contraceptive precautions must be used. If you are in doubt about any of these medicines ask your doctor or pharmacist. As this medicine may interfere with urine tests for glucose, causing the test to give a &ldquo;false positive&rdquo; result. That is, the test may say that glucose is present in the urine even if it is not. This medicine may also cause your urine to turn yellow or brown. Inform your doctor or pharmacist if you&nbsp;suffer from any other illnesses&nbsp;have any allergies or are taking any other medications (including non-prescription medications). Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;<br />&nbsp;<br />d. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. As far as it is known UvaminTM 100 mg retard may be used in pregnancy. However, it should not be used during final stages of pregnancy (labour and delivery) because there is a possibility that use at this stage may affect the baby. If you want to breast feed, please consult your doctor first. Ask your doctor for advice before taking any medicine.&nbsp;<br />&nbsp;<br />e. Driving and using machines This medicine may alter responsiveness to such an extent that the ability to drive and use tools or machines is impaired. UvaminTM 100 mg retard may cause dizziness. You should not drive or operate machinery until symptoms go away.&nbsp;<br />&nbsp;<br />f. Important information about some of the ingredients of Uvamin&trade; This medicine contains lactose. If you have been told by your doctor that you are intolerant to some sugars and have to avoid them, contact your doctor before taking this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take UvaminTM 100 mg retard exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Your doctor will decide on the dose of UvaminTM 100 mg retard. Unless otherwise prescribed by the doctor, the following indications apply: Adults Acute urinary tract infections Take one capsule 2-3 times daily for 7-10 days. Long-term treatment of chronic urinary tract infections Take one capsule 1-2 times daily. Children below 12 years of age UvaminTM 100 mg retard capsules are not recommended for use in children below 12 years. The prolonged-release capsules should be swallowed whole without chewing. Take with plenty of liquid at mealtimes. Once started, treatment with UvaminTM 100 mg retard should be continued for the entire duration prescribed by the doctor. Do not change the daily dose or the duration of treatment without consulting your doctor or pharmacist. Symptoms of disease often disappear before the infection is completely cured. If the treatment period is too short or if treatment is ended too early, the infection may flare up again. Do not change the prescribed dosage of your own accord. If you think the effect of this medicine is too strong or too weak, talk to your doctor or pharmacist.&nbsp;<br />&nbsp;<br />If you take more Uvamin&trade; than you should If you take too much UvaminTM 100 mg retard contact your doctor or your nearest hospital emergency department immediately. If possible, show them the UvaminTM 100 mg retard pack, so that the medical staff knows what you have taken. If you have any further questions on the use of this product, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, UvaminTM 100 mg retard can cause side effects, although not everybody gets them.&nbsp;<br />&nbsp;<br />If you notice the following symptoms, stop treatment with UvaminTM 100 mg retard immediately and inform your doctor without delay:  sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (especially affecting your whole body). These are the signs of serious allergic reactions;  abnormal sensations in the hands and/or feet, headache, dizziness, extreme changes of mood or mental state (depression, euphoria, confusion or other psychotic reactions), &nbsp;weakness, blurred vision or nystagmus (uncontrollable, rhythmic movements of an&nbsp;organ, most commonly the eye). These neurological effects may be severe and in some instances permanent;  your lungs may react to nitrofurantoin. This may develop quickly, with sudden shortness of breath, cough, fever and pain behind the breastbone, or slowly with the listed symptoms (including the sensation of breathlessness in the recumbent position, relieved by sitting or standing), especially in elderly patients;  jaundice (yellowing of the skin or whites of the eyes), especially accompanied by fatigue, abdominal pain, joint pain and swelling as signs of liver inflammation (autoimmune hepatitis). &nbsp; raised pressure in the skull (causing severe headaches);  severe reduction in blood cells which can cause weakness, bruising or make infections more likely;&nbsp;<br />&nbsp;<br />The following side effects may occur during the treatment with UvaminTM 100 mg retard:&nbsp;<br />&nbsp;<br />Uncommon (may affect up to 1 in 100 people)  peripheral neuropathy (changes to the sense of feeling and the use of muscles, blurred vision, confusion, extreme changes of mood or mental state, dizziness, weakness, headache, somnolence) &nbsp; allergic lung reaction (called nitrofurantoin pneumonia) with episodes of coughing, shortness of breath and chest pain, particularly during long-term therapy  vomiting (being sick)  stomach pain &nbsp; diarrhea&nbsp;<br />&nbsp;<br />Rare (may affect up to 1 in 1,000 people)  a decrease in the number of blood cells (agranulocytosis, eosinophilia, leukopenia, granulocytopenia, glucose-6-phosphatedehydrogenase deficiency anaemia, haemolytic anaemia, thrombocytopenia and megaloblastic anaemia, aplastic anaemia)  allergic skin reactions (including severe)  inflammation of the pancreas &ndash; signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting)  liver disorders (yellowing of the whites of the eyes or skin and inflammation of the liver) &nbsp; erythema nodosum (inflammation of the fat cells under the skin, resulting in red nodules)  temporary hair loss  increased occurrence of crystals in the urine sediment (crystalluria)  reversible disorders of spermatogenesis &nbsp;<br />&nbsp;<br />Very rare (may affect up to 1 in 10,000 people)  outbreaks of sweating &nbsp; feeling of weakness &nbsp; globus symptoms (&quot;lump in the throat&quot; sensation)&nbsp;<br />&nbsp;<br />Not known (cannot be estimated from the available data)  lupus-like syndrome (reversible autoimmune disorder)  hypersensitivity reactions, including anaphylaxis, drug fever and joint pain  benign intracranial hypertension (raised pressure in the skull causing severe headaches)  feeling sick (nausea) &nbsp; anorexia (eating disorder that is characterized by self-starvation and excessive weight loss)  additional infections caused by microorganisms which are not sensitive to nitrofurantoin&nbsp;<br />&nbsp;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.&nbsp;<br />&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep out of the reach and sight of children. &nbsp;Do not store above 30 &ordm;C. UvaminTM 100 mg retard may be used only up to the date marked with &ldquo;EXP&rdquo; on the pack. Once you have finished treatment, take the remaining medicine to your dispenser (doctor or pharmacist) for correct disposal. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is nitrofurantoin. &nbsp;Each capsule of UvaminTM 100 mg retard contains 100 mg of nitrofurantoin.&nbsp;<br />&nbsp;<br />The other ingredients are: &nbsp;Capsule fill: hypromellose, lactose monohydrate, cellulose microcrystalline, purified water. Capsule shell: hard gelatin capsule shell, gelatine, quinoline yellow, titanium dioxide.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Uvamin™ 100 mg retard is hard gelatin capsule, size No 2, with yellow cap and body, and the imprint “100”. 
 
Uvamin 100 mg retard capsules are packed in PVC/PVDC – Aluminium blisters, which are packed in carton box. Each pack contains 2 blisters each of 10 capsules. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorization Holder&nbsp;<br />&nbsp;<br />Acino Pharma AG, Liesberg, Switzerland&nbsp;<br />&nbsp;<br />Manufacturer&nbsp;<br />&nbsp;<br />Acino Pharma AG, Aesch, Switzerland&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;<br />يحتوي يوفامين ريتارد&nbsp; ١٠٠ مجم كبسوﻻت على&nbsp;١٠٠&nbsp;مجم من نتروفورانتوين. نتروفورانتوين&nbsp;هو دواء مضاد للبكتيريا . يستخدم يوفامين&nbsp;ريتارد &nbsp;١٠٠ مجم كبسوﻻت لعﻼج اضطرابات المسالك البولية الحادة والمزمنة النﱠاجمة ع الكائنات الدﱠقيقة الحساسة للنتروفورانتوين )على سبيل المثال :وي التهاب المثانة، عدوى الحوض الكل &nbsp;.(ا ً ستخدم أيض ُ قد ي للوقاية من العدوى أثناء الفحوصات )على سبيل المثال :منظار المثانة (أو بعد الخضوع للجراحة في الجهاز البولي. &nbsp;ة ١٠٠ريتارد &nbsp;&trade;يجب عدم استخدام يوفامين ﱠ بناء على وصفة طبي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;:في الحاﻻت اﻵتية&trade; أ. &nbsp;ﻻ تتناول يوفامين<br />&nbsp;<br />&nbsp;: مجم في الحاﻻت اﻵتية ١٠٠ ريتارد &nbsp;&trade;ﻻ تتناول يوفامين - &nbsp;اً ) ؤثر بشدة على كيفية عملها ُ لى ي ُ إذا كنت تعاني من مرض في الك &nbsp;،( استشر طبيبك إذا لم تكن متأكد - إذا كنت تعاني من قلة البول أو عدم إخراج البول، &nbsp;- ة إذا كنت تعاني من مرض بالجهاز العصبي مثل اعتﻼل اﻷعصاب الطرفي)اب اعتﻼل اﻷعص (أو ب التهاب عص &nbsp;،( طرفي أو التهاب عصب في المخ )التهاب العصب - م عرف باس&quot;وز ُ إذا كنت تعاني من مرض وراثي نادر بخﻼيا الدﱠم الحمراء ي -٦ - نقص نازعة هيدروجين الجلوك &nbsp;،&quot;فوسفات &nbsp;،( - مرض محدد بالرئة )تليف رئوي - &nbsp;ﱠ ؤثر على إنتاج الصبغة الحمراء في الدم )ة ُ ا باضطراب ي ً إذا كنت مصاب ،( يﱠة الحاد ِ فير ْرُ الب<br />- &nbsp; &nbsp;عاني من حساسية معروفة تجاه نتروفورانتوين ُ إذا كنت ت ) من المكونات اﻷخرى بهذا الدﱠواء ٍّ أو تجاه أي درجة في ُ الم .افية ٦ قسم معلومات إض .(ال تشمل أعراض فرط الحساسية على سبيل المث :طرابات الربو، ضيق النفس، اض . تورم الجلد )على سبيل المثال :طفح القراص (واﻷغشية المخاطية أو الطفح الجلدي ، بالدﱠورة الدموية - &nbsp;، ( في المراحل النهائية من الحمل)المخاض أو الوﻻدة ِ إذا كنت ؤثر على الجنين ُ ؛ حيث قد يكون هناك خطر ي - إذا كان طفلك بعمر أقل من ثﻼثة أشهر، - &nbsp;ا لطفل يشتبه أو معروف إصابته بنقص في إ وز ً مرضع ِ إذا كنت - فات ٦ سمى نازعة هيدروجين الجلوك ُ نزيم ي فوس )G٦PD.( &nbsp;. سنة ١٢ مجم في اﻷطفال أقل من ١٠٠ريتارد &nbsp;&trade; وصى باستخدام كبسوﻻت يوفامين ُ ﻻ ي<br />&nbsp;<br />ب. &nbsp;ا مع ا خاص ً توخ حذر ارد &nbsp;&trade; تحدﱠث إلى طبيبك قبل تناول يوفامين اه ١٠٠ ريت مجم إذا تعرضت لﻺصابة بأي من اﻵثار الجانبية المدرجة أدن &nbsp;اﻵثار الجانبية المحتملة (&quot;ابق ب ٤&quot; )انظر قسم أثناء العﻼج السوين نتروفورانت )امين ارد &nbsp;&trade; المادة الفعالة في يوف ١٠٠ ريت مجم .(على وجه الخصوص، يجب ذكر أعراض الكبد والجلد. &nbsp;إذا كنت تعاني من أي مرض بالرئتين أو ا از ، لى ُ يجب عليك إبﻼغ طبيبك إذا كانت لديك أي مشاكل بالك لكبد أو الجه العصبي، إذا كنت تعاني من فقر دم )ﱡس ،( فَ التﱠن َ رْسُ وع َ ا بالجلد، ضعف ً سبب شحوب ُ انخفاض في تعداد خﻼيا الدﱠم الحمراء ي ارد &nbsp;&trade; ي أو ضعف حركي أو نقص فيتامين ب .إذا كنت بحاجة لتناول يوفامين ِ مرض السﱡكﱠر دة ١٠٠ ريت مجم كبسوﻻت لع أشهر، فقد يرغب طبيبك في فحص كيفية عمل رئتيك وكبدك بشكل منتظم. &nbsp;- فوسفات، والذي ٦ أخبر طبيبك إذا كنت تعاني من نقص بإنزيم )مادة كيميائية بالجسم (يسمى نازعة هيدروجين الجلوكوز يسبب تلف خﻼيا الدﱠم الحمراء لديك بشكل أكثر سهولة.&nbsp;<br />&nbsp;<br />ج. &nbsp;تناول أدوية أخرى يجب إبﻼغ طبيبك إذا كنت تتناول أدوية معينة لعﻼج العدوى، على سبيل المثال :تلك اﻷدوية التي تحتوي على المادة الفعالة حمض الناليديكسيك، اﻷدوية التي تزيد من إفراز حمض اليوريك )رس أدوية عﻼج مرض النق (واد التي تحتوي على الم ﱠ الفعالة سلفينبيرازون أو بروبنيسيد، اﻷدوية التي تحتوي على المادة الفع طرابات ستخدم لعﻼج اض ُ الة فينيتوين، والتي ت نوبات التشنج )الصرع (ة . ستخدم لمنع إفراز حمض المعد ُ والتي ت ، أو اﻷدوية التي تحتوي على البروبانثيلين ا ﻷنﱠ التناول المتزامن لبعض مضادات الحموضة )دة ً نظر ستخدم لعﻼج فرط حمض المع (اص ُ أدوية ت يخفض من امتص نتروفورانتوين، فيجب تناول نتروفورانتوين قبل ساعة واحدة على اﻷقل من تناول مضادات الحموضة. &nbsp; الذي يعطى للوقاية ، ا أو قد تتناول لقاح التيفود ً رجى إبﻼغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخر ُي من التيفود. يمنع نتروفورانتوين ب التﱠأثير المضاد للبكتيريا ل عض اﻷدوية اﻷخرى المستخدمة لعﻼج عدوى المسالك البولية. ضعف وين ُ كما هو الحال مع المضادات الحيوية اﻷخرى، قد ي نتروفورانت ة ؤدي إلى خفض فعالي ُ النبيتات المعوية، مما ي بعض موانع الحمل .يجب استخدام احتياطات إضافية لمنع الحمل. إذا كانت تساورك الشكوك حول أي من هذه اﻷدوية، فاستشر الطبيب أو الصيدلي الخاص بك. سبب إعطاء اﻻختبار نتيجة &quot;ة ُ ا ﻷنﱠ هذا الدﱠواء قد يتداخل مع اختبارات البول لقياس نسبة الجلوكوز، مما ي ً نظر إيجابي كاذبة .&quot;ك أي أنﱠ اﻻختبار قد يبين أن الجلوكوز موجود في البول حتى لو لم يكن كذل . ﱠ قد يسبب هذا الد ول ا تحول الب ً واء أيض لديك إلى اللون اﻷصفر أو البني. أخبر طبيبك أو الصيدلي الخاص بك: &nbsp; إذا كنت تعاني من أية أمراض أخرى  &nbsp;إذا كان لديك أية حساسية أو  .( إذا كنت تتناول أية أدوية أخرى )بما في ذلك اﻷدوية التي تحصل عليها دون وصفة طبية  رجى إبﻼغ طبيبك أو الصيدلي ي ُي ا أية أدوية أخرى، بما في ذلك اﻷدوية الت ً إذا كنت تتناول أو تناولت مؤخر حصلت عليها دون وصفة طبية.&nbsp;<br />&nbsp;<br />د. &nbsp;الحمل والرضاعة الطبيعية &nbsp;لُ فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناو ، حامل أو تخططين لذلك ِ أو تعتقدين أنك ،اً أو مرضع ً حامﻼ ِ إذا كنت هذا الدﱠواء. &nbsp;ل ١٠٠ريتارد &nbsp;&trade; بقدر ما هو معروف أن يوفامين ستخدم أثناء الحم .ل ُ مجم قد ي مع ذلك، يجب عدم استخدامه خﻼل المراح اﻷخيرة من الحمل )المخاض والوﻻدة (ين ؤثر على الجن .ت ُ بسبب وجود احتمال بأنﱠ اﻻستخدام أثناء هذه المرحلة قد ي إذا كن ً . أوﻻ ِ فيرجى استشارة طبيبك ، تنوين اﻹرضاع استشيري طبيبك قبل تناول أي دواء.&nbsp;<br />&nbsp;<br />ه. &nbsp;القيادة واستخدام اﻵﻻت قد يغير هذا الدﱠواء ي فتخدام اﻷدوات أو اﻵﻻت ضعف القدرة على القيادة واس .بب ُ اﻻستجابة إلى الحد الذي ي سُ قد ي . مجم &nbsp; دوخة .يجب تجنب القيادة أو تشغيل اﻵﻻت حتى تزول اﻷعراض ١٠٠ريتارد &nbsp;&trade;يوفامين<br />&nbsp;<br />و. &nbsp;معلوم ن &trade; ات هامﱠة عن بعض مكونات يوفامي يحتوي هذا الدﱠواء على سكر ﻻكتوز .ا، إذا كان طبيبك قد أخبرك بأنك ﻻ تتحمل بعض أنواع السكريات ويجب عليك تجنبه فاتصل بطبيبك قبل تناول هذا الدﱠواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;<br />&nbsp;مجم ب ١٠٠ريتارد &nbsp;&trade;تناول يوفامين . ا كما أخبرك طبيبك الضبﻂ ً دائم . ا من كيفية التناول ً يجب مراجعة طبيبك أو الصيدلي إذا لم تكن متأكد مجم .ة ١٠٠ريتارد &nbsp;&trade;سيحدد طبيبك الجرعة من يوفامين : يتم تطبيق اﻹرشادات التﱠالي ، ما لم يصف الطبيب خﻼف ذلك البالغون عدوى المسالك البولية الحادة &nbsp;ا لمدة ٣-٢تناول كبسولة واحدة &nbsp;. أيام ١٠-٧ مرات يومي العﻼج طويل اﻷمد لعدوى المسالك البولية المزمنة تناول كبسولة واحدة مرة واحدة إلى مرتين يوميا. اً ١٢اﻷطفال اﻷقل من عام اً ١٢ مجم في اﻷطفال اﻷقل من ١٠٠ريتارد &nbsp;&trade;ﻻ يوصى باستخدام يوفامين عام. يجب بلع الكبسوﻻت ممتدة اﻹفراز بالكامل وﻻ يتم مضغها. تناوله مع كمية كبيرة من السائل في وقت تناول الوجبات. &nbsp;ب ١٠٠ريتارد &nbsp;&trade;بمجرد بدء العﻼج بيوفامين مجم ، فيجب مواصلته طوال المدة المحددة من قبل الطبي .ة ﻻ تغير الجرع اليومية أو مدة العﻼج دون استشارة طبيبك أو الصيدلي الخاص بك .ن ا ما تختفي أعراض المرض قبل الشفاء التﱠام م ً غالب اً .العدوى . فقد تتفاقم العدوى مجدد ،اً إذا كانت فترة العﻼج قصيرة جدا أو إذا انتهى العﻼج مبكر ﻻ تغير الجرعة الموصوفة من تلقاء نفسك . إذا شعرت أنﱠ تأثير الدﱠواء أقل من الﻼزم أو أقوى من الﻼزم، فتحدﱠث إلى طبيبك أو الصيدلي الخاص بك.&nbsp;<br />&nbsp;<br />&nbsp;أكثر مما يجب &trade;إذا تناولت يوفامين ك ١٠٠ريتارد &nbsp;&trade; إذا تناولت كمية كبيرة جدا من يوفامين . ا بطبيبك أو قسم الطﱠوارئ بأقرب مستشفى ل ً مجم، فاتصل فور . مجم ، حتى يعرف الطاقم الطبي ما الذي تناولته ١٠٠ريتارد &nbsp;&trade; وإذا أمكن، أظهر لهم عبوةيوفامين إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;اﻵثار الجانبية الم ع ١٠٠ريتارد &nbsp;&trade; سبب يوفامين ُ قد ي ، مثله مثل كافة اﻷدوية . على الرﱠغم من عدم حدوثها لدى الجمي ، ا جانبية ً مجم آثار<br />&nbsp;<br />&nbsp;ر ١٠٠ريتارد &nbsp;&trade; فتوقف عن العﻼج بيوفامين ، إذا ﻻحظت اﻷعراض التﱠالية : ا وأبلغ طبيبك دون تأخي ً مجم فور ة  ا أو حك)ؤثر ً طفح ، تورم الجفون أو الوجه أو الشفتين ، صعوبة في التﱠنفس ، ا بالصدر ً ا مفاجئ ً أزيز ُ التي ت ً خاصة على جسمك بالكامل .(هذه عﻼمات على اﻹصابة بتفاعﻼت حساسية خطيرة. &nbsp;أحاسيس غير طبيعية باليدين و/ ة ال  تغيرات شديدة في الحالة المزاجية أو الحالذه ة ، دوخة ،اً صداع ، أو القدمين ني )ا / رى ً ارتباك ، نشوة ،اً اكتئاب ا أو أي تفاعﻼت ذهانية أخ(ة أو رأرأة ً التباس عدم وضوح الرؤي)ات ،اً ، ضعف حرك نظا ن ا بالعي .(ديدة ً وتكون أكثر شيوع ، مية ﻻ يمكن التحكم فيها ﻷحد اﻷعضاء قد تكون هذه التأثيرات العصبية ش وتكون دائمة في بعض الحاﻻت. &nbsp;قد تتفاعل رئتيك مع نتروفورانتوين .عال،  قد يتطور هذا اﻷمر بسرعة، مع حدوث ضيق مفاجئ في التنفس، س حمى وألم وراء عظم الصدر، أو ببﻂء مع اﻷعراض المذكورة )ي و فﱡس فع َ ر التﱠن ْسُ بما في ذلك اﻹحساس بع ض اﻻستلقاء، يزول عند الجلوس أو الوقوف(ن . في المرضى من كبار الس ً خاصة ، اليرقان )ين  اصفرار الجلد أو بياض العين(ورم ا بالمفاصل والتﱠ ً ألم ، ا بالبطن ً ألم ، المصحوب باﻹرهاق ً ، خاصة باعتبارها عﻼمات ﻻلتهاب الكبد )التهاب الكبد المناعي الذاتي .( &nbsp;.( ارتفاع الضغﻂ داخل الجمجمة )مما يسبب حاﻻت صداع شديدة <br /><br />&nbsp;ى  . رضة لﻺصابة بالعدو ُ اﻹصابة بكدمات أو يجعلك أكثر ع ،اً سبب ضعف ُ ا في خﻼيا الدﱠم والذي قد ي ً ا شديد ً انخفاض<br />&nbsp;<br />&nbsp; مجم: ١٠٠ ريتارد TM قد تحدث اﻵثار الجانبية التﱠالية اثناء فترة العﻼج بيوفامين<br />&nbsp;<br />غير شائعة )إ ( شخص ١٠٠ ؤثر على ما يصل لى شخص واحد من بين كل ُ قد ت اعتﻼل العصب الطرفي )اك  تغيرات باﻹحساس أو الشعور واستخدام العضﻼت، عدم وضوح الرؤية، ارتب/ اس، التب تغيرات شديدة بالحالة المزاجية أو الحالة الذهنية، دوخة، ضعف، صداع، النيمومة (  تفاعل رئوي ت ي حسس)وي يسمى التهاب رئوين نتروفورانتي (در، ا بالصً مع نوبات من السعال وضيق النﱠفس وألم وخاصة خﻼل العﻼج طويل اﻷمد. &nbsp;.( القيء )اﻹعياء  ة  &nbsp;. ا بالمعد ً ألم  &nbsp;ً إسهاﻻ.&nbsp;<br />&nbsp;<br />نادرة ) &nbsp;( شخص ١٠٠٠ ؤثر في ما يصل إلى شخص واحد من بين كل ُ قد ت  &nbsp;ا في تعداد خﻼيا الدﱠم)ﱠ ً انخفاض ي ا ِ وزين ُ ندرة خﻼيا المحببات، كثرة خﻼيا الي ضاء، قلة خﻼي ْ الدﱠم البي ِ يﱠات َ كر ُ قلﱠة ، ات المحببات، &nbsp; - ة ٦ فقر دﱠم نقص إنزيم نازعة هيدروجين الجلوكوز فوسفات، فقر الدﱠم اﻻنحﻼلي، نقص الصﱠفائح الدﱠموي .( فقر الدﱠم غير التنسجي ، وفقر الدﱠم ضخم اﻷرومات ( تفاعﻼت جلدية تحسسية )بما في ذلك التفاعﻼت الشديدة  التهاب البنكرياس - ا  ديدا ً تشمل العﻼمات ألم شاء ا مع شعور باﻹعي)ان ً غالب ، في الجزء العلوي من المعدة غثي (أو اﻹعياء )القيء.( &nbsp; .( اضطرابات الكبد )اصفرار بياض العينين أو الجلد والتهاب الكبد  ا  ا عقدي)ة ً احمرار د) (التهاب الخﻼيا الدهنية تحت ال ء ِقَ مامى ع ُح .( ؤدي إلى وجود عقيدات حمرا ُ مما ي ، جلد ر  . ا للشع ً ا مؤقت ً تساقط زيادة نسبة وجود البلورات في رواسب البول)ت  .( لﱠورا ِ ة الب َيل ِب &nbsp;. اضطرابات تكون الحيوانات المنوية القابلة لﻼرتداد <br />&nbsp;<br />نادرة جدا ) &nbsp;.( شخص ١٠٠٠٠ من كل ١ ؤثر في ما يصل إلى ُ قد ت اً  &nbsp;. ا شديد )متفشيا( ً تعرق &nbsp;. الشعور بالضعف  قْ أعراض اﻹحساس بوجود كرة )الشعور &quot;بوجود كرة  .(&quot; لَ في الح<br />&nbsp;<br />غير معروفة )ﻻ يمكن تقديرها من واقع البيانات المتاحة(  &nbsp;ِ .( ة )اضطراب مناعي ذاتي قابل لﻼرتداد َبْئِّ بالذ ٌةَ بيه َ ش ٌةَمِزَﻼَتُم ا  . حمى الدﱠواء وألم ب لمفاصل ، بما في ذلك تأق ، تفاعﻼت فرط الحساسية ارتفاع الضغﻂ الحميد داخل الجمجمة )ة  .( سبب حاﻻت صداع شديد ُ ارتفاع الضغﻂ داخل الجمجمة مما ي &nbsp;.( الشعور باﻹعياء )غثيان  فقدان الشهية )د  اضطراب بتناول الطعام يتسم بالتﱠجويع الذاتي وفقدان الوزن الزائ.( &nbsp;. عدوى إضافية تسببها كائنات دقيقة غير حساسة لنتروفورانتوين <br />&nbsp;<br />رجى إبﻼغ الطبيب ُ في ، أو إذا ﻻحظت أية آثار جانبية غير الواردة في هذه النﱠشرة ،اً إذا أصبح أيﱞ من اﻵثار الجانبية خطير أو الصيدلي الخاص بك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;. كيفية تخزين يوفامين<br />&nbsp;<br />&nbsp; . ا عن متناول ورؤية اﻷطفال ً يحفظ بعيد . درجة مئوية ٣٠ ﻻ تقم بالتﱠخزين في درجة حرارة تتعدى &nbsp;١٠٠ ريتارد TM يمكن استخدام يوفامين .&quot;EXP&quot; مجم فقﻂ حتى التﱠاريخ المدون على العبوة بعد كلمة خذ الدﱠواء المتبقي لمن صرفه لك )الطبيب أو الصيدلي (ة ، بمجرد اﻻنتهاء من العﻼج للتﱠخلص منه بطريقة صحيح.&nbsp;<br />يجب عدم التﱠخلص من اﻷدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية .ن اسأل الصيدلي الخاص بك ع كيفية التﱠخلص من اﻷدوية التي لم تعد بحاجة إليها .ة&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">المادة الفعالة هي نتروفورانتوين . &nbsp;. مجم من نتروفورانتوين ١٠٠ مجم على ١٠٠ريتارد TMتحتوي كل كبسولة من يوفامين&nbsp;<br />&nbsp;<br />المكونات اﻷخرى هي : محتويات الكبسولة :ى . نق ُ ماء م ، سليلوز دقيق التبلور ، ﻻكتوز أحادي الهيدرات ، هيبروميلوز غﻼف الكبسولة :غﻼف كبسولة جيﻼتيني صلب، جيﻼتين، كينولين أصفر، ثاني أكسيد التيتانيوم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;<br />&nbsp;ارد TM يوفامين م ١٠٠ ريت مجو هم فر، ٢ عبارة عن كبسولة جيﻼتينية صلبة، بحجم رق ، ذات غﻼف وجسم لونه أص .&quot;١٠٠&quot;ومطبوع عليها&nbsp;<br />&nbsp;<br />&nbsp;ارد TM عبأ يوفامين ُي د ١٠٠ ريت مجم كبسوﻻت في عبوات من بولي فينيل الكلوري/ د بولي فينيليدين كلوري- ن شرائﻂ م اﻷلومنيوم، وهي تكون معبأة في عبوات كرتونية. &nbsp;. كبسوﻻت ١٠تحتوي كل عبوة على شريطين بكل شريﻂ&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التﱠسويق&nbsp;<br />&nbsp;<br />شركة أسينو فارما شركة مساهمة، ليزبيرج، سويسرا.&nbsp;<br />&nbsp;<br />جهة التﱠصنيع&nbsp;<br />&nbsp;<br />شركة أسينو فارما شركة مساهمة، أيش، سويسرا.&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر  2018 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uvamin™ 100 mg retard capsules 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance Each Uvamin™ 100 mg retard capsule contains: nitrofurantoin 100 mg. 
 
Excipients Colouring agent: E104; excipients for capsule (for a full list of excipients, see section 6.1.) Each capsule contains lactose monohydrate 20 mg per capsule. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard gelatin capsule, size No 2. Uvamin™ 100 mg retard hard capsule has yellow cap and body with the imprint “100”. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Acute infections of the efferent urinary tract, particularly if there is resistance to other antimicrobial agents. Chronic infections of the efferent urinary tract. Infection prophylaxis in diagnostic examinations or following surgery on the urinary tract system. Official recommendations on the appropriate use of antibiotics should be followed, particularly recommendations for use regarding the prevention of increased antibiotic resistance.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Adults &nbsp;Acute urinary tract infections One Uvamin&trade; 100 mg retard capsule 2-3 times daily for 7-10 days.&nbsp;<br />&nbsp;<br />Chronic urinary tract infections (long-term treatment) One Uvamin&trade; 100 mg retard capsule 1-2 times daily for several weeks or months.&nbsp;<br />&nbsp;<br />Children &nbsp;Uvamin&trade; 100 mg retard is not recommended for use in children under 12 years.&nbsp;<br />&nbsp;<br />Elderly &nbsp;No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 60 mL/min. See precaution and risks to elderly patients associated with long-term therapy (see section 4.4). Renal impairment &nbsp;Nitrofurantoin should be administered only if renal function is normal (creatinine clearance values over 60 ml/min) and when lower-risk antibiotics and chemotherapeutic agents cannot be employed (see sections 4.3 and 4.4).&nbsp;&nbsp;<br />&nbsp;<br />Hepatic impairment &nbsp;No dose adjustment is necessary in patients with hepatic function disorders. See special warnings and precautions for use (see section 4.4).&nbsp;<br />Method of administration For oral administration. To improve tolerability, nitrofurantoin should be taken during or immediately after meals with sufficient liquid.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nitrofurantoin is contraindicated:  in patients with known hypersensitivity to nitrofurantoin, other nitrofurans or to any of the excipients  in patients with renal dysfunction with creatinine clearance below 60 ml/min or with elevated plasma creatinine levels  in cases of glucose-6-phosphate dehydrogenase deficiency (see “Pregnancy/Lactation”)  in cases of acute porphyria  in infants under 3 months of age and in the final stages of pregnancy (during labour and delivery), due to the theoretical possibility of haemolytic anaemia in the foetus or neonate (under 3 months) resulting from the immature red blood cell enzyme system  Oliguria, anuria. Polyneuropathy, neuritis. Pulmonary fibrosis. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Nitrofurantoin should be administered only if renal function is normal (creatinine clearance values over 60 ml/min) and when lower-risk antibiotics and chemotherapeutic agents cannot be employed. The utmost caution is advised in patients with impaired renal excretion, since insufficient elimination can lead to accumulation whilst, at the same time, the urinary active substance concentration may be significantly reduced. During long-term therapy, the patient&rsquo;s pulmonary function must be monitored regularly (especially in the case of elderly patients). Early detection of nitrofurantoin-induced pulmonary hypersensitivity reactions and, if necessary, immediate discontinuation of nitrofurantoin treatment are important in impeding progression and avoiding potentially irreversible damage. Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonia) can develop unnoticed and are common in elderly patients. In recurrent or severe cases, a surgical basis for the infection should be ruled out. As pre-existing conditions can mask side effects affecting the lungs or liver, nitrofurantoin should be used with caution in patients with pulmonary diseases, hepatic function disorders, neurological conditions and allergic diathesis. Peripheral neuropathy and susceptibility to peripheral neuropathy, which can become severe or irreversible, have been observed and can become life-threatening. Treatment should be discontinued at the first signs of nerve involvement (paraesthesia). Caution is advised in cases of anaemia, diabetes mellitus, electrolyte imbalances, paresis and vitamin B deficiency (especially folate deficiency), as the risk of peripheral neuropathy is increased in such cases. Nitrofurantoin should be immediately stopped at the first signs of tingling or numbness in the extremities. Patients should be monitored closely for signs of hepatitis (especially during relatively long-term administration). The urine may turn yellow or brown after nitrofurantoin administration. False positive urinary glucose test results may occur in patients treated with nitrofurantoin, if the test detects reducing substances in the urine. Nitrofurantoin must be discontinued at the first signs of haemolysis in patients with suspected glucose-6-phosphate dehydrogenase deficiency.</p><p dir="ltr"><br />Gastrointestinal reactions can be reduced by taking the medication with food or milk, or by adapting the dose. During long-term therapy the patient must be monitored closely for the occurrence of hepatic or pulmonary symptoms or other evidence of toxicity. Monitoring of the blood count, renal function and hepatic function, together with neurological examinations, are essential during prolonged therapy. Nitrofurantoin must be discontinued if pulmonary, hepatic, haematological or neurological syndromes that cannot be otherwise explained should occur. Nitrofurantoin is not indicated for urinary tract infections which may be accompanied by parenchymal involvement and/or bacteraemia (pyelonephritis, acute cystitis in men), or in cases of urethritis (usually caused by gonococci, Chlamydia and/or Mycoplasma) or prostatitis (inadequate penetration of nitrofurantoin into the prostate secretion). Upon administration of nitrofurantoin, proliferation of resistant microorganisms (especially Pseudomonas) can occur. Appropriate treatment must be instituted at the onset of such superinfections. This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Nitrofurantoin antagonises the activity of nalidixic acid and other gyrase inhibitors in vitro but the clinical relevance of this interaction is unclear. Nitrofurantoin can lower the plasma concentrations of phenytoin, thereby possibly reducing the efficacy of phenytoin. Propantheline increases the urinary concentration of nitrofurantoin, probably as a result of improved absorption due to inhibition of gastric emptying. Co-administration of sulphinpyrazone or probenecid can lead to the inhibition of renal excretion and hence to decreased activity and increased toxicity of nitrofurantoin. Magnesium trisilicate antacids can decrease nitrofurantoin absorption and should therefore not be administered concurrently, but at least 1 hour later. The effect of nitrofurantoin is decreased by interaction with sodium bicarbonate, sodium lactate and other urine-alkalising agents. The antibacterial effect is reduced by carbonic anhydrase inhibitors and alkalisation of the urine. Interaction with certain urinary glucose tests. As nitrofurantoin belongs to the group of antibacterial agents, the following interactions are to be expected:  Oestrogens: As with other antibiotics, nitrofurantoin can compromise the intestinal flora, which leads to lower absorption of oestrogens and reduced effectiveness of oestrogen-containing contraceptives. Therefore, female patients must be warned appropriately and additional contraceptive precautions must be used.  The oral typhus vaccine is inactivated by antibacterial agents.&nbsp;<br />&nbsp;<br />Interference with diagnostic methods Nitrofurantoin gives false-positive results in the sugar test with copper sulphate solution (Benedict&#39;s reagent, Clinitest). Glucose oxidase methods are not affected (Clinistix, Tes-tape). Possible yellowing/browning of the urine can result in too high or false-positive laboratory values (bilirubin, BUN).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pregnancy There are no adequate data available on the use of nitrofurantoin in pregnant women. Studies in animals have shown reproductive toxicity (see &ldquo;Preclinical data&rdquo;). Use is contraindicated in the third trimester of pregnancy (risk of haemolytic anaemia in the neonate). Uvamin&trade; 100 mg retard should not be used during the first 6 months of pregnancy unless clearly necessary. Due to the potential risk of haemolysis of immature red blood cells in the neonate, nitrofurantoin is, however, contraindicated in babies under 3 months of age and in the final stages of pregnancy (during labour and delivery).&nbsp;<br />&nbsp;<br />Breastfeeding The breast-feeding of babies suspected or known to be suffering from red blood cell enzyme deficiency (including G6PD deficiency) must be avoided as traces of nitrofurantoin are detected in human milk.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Even when used as directed, this medicinal product may alter the reactions to such an extent that the ability to drive and use machines is impaired. This applies all the more in combination with alcohol.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), &nbsp;unknown (cannot be estimated from the available data). &nbsp;Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Tabulated list of adverse reactions&nbsp;<br />&nbsp;<br />Table 1</p><p dir="ltr">Blood and lymphatic system disorders&nbsp;<br />&nbsp;<br />Rare: agranulocytosis, eosinophilia, leukopenia, granulocytopenia, haemolytic anaemia, glucose-6-phosphate dehydrogenase deficiency, thrombocytopenia and megaloblastic anaemia. Aplastic anaemia. The blood count generally returned to normal after discontinuation of treatment.&nbsp;<br />&nbsp;<br />Immune system disorders&nbsp;<br />&nbsp;<br />Rare: exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome). Lyell&#39;s syndrome, anaphylactic shock after nitrofurantoin, autoimmune reactions after nitrofurantoin, usually in association with chronic pulmonary or hepatic reactions. Allergic skin reactions such as maculopapular, erythematous or eczematous rashes, urticaria, rash, angioedema and pruritus. Unknown: lupus-like syndrome, which is associated with pulmonary reactions to nitrofurantoin. Other hypersensitivity reactions include anaphylaxis, drug fever and arthralgias.&nbsp;<br />&nbsp;</p><p dir="ltr">&nbsp;<br />Nervous system disorders Uncommon: peripheral neuropathy (including optic neuritis) with sensory and motor symptoms that can become severe or irreversible. Less common reactions of unknown aetiology: depression, euphoria, confusion, psychotic reactions, nystagmus, dizziness, asthenia, headache and somnolence. Treatment must be discontinued at the first sign of neurological effects. Unknown: benign intracranial hypertension.&nbsp;<br />&nbsp;<br />Respiratory, thoracic and mediastinal disorders Treatment with UvaminTM 100 retard must be discontinued if any of the following respiratory reactions occur. Uncommon: allergic pulmonary infiltration (called nitrofurantoin pneumonia) with episodes of coughing, dyspnoea and retrosternal pain may rarely lead to irreversible pulmonary fibrosis, particularly during long-term therapy. A differentiation is made between acute, subacute and chronic forms of pulmonary reactions. The acute form occurs with clinical symptoms of allergic pulmonary oedema, with sudden dyspnoea, coughing, fever and, notably, pulmonary infiltration (nitrofurantoin pneumonia), generally appearing some hours after the last nitrofurantoin dose. Upon discontinuation of the product, such syndromes resolve within 2-3 weeks. The subacute form, which can normally occur approximately 1 month after nitrofurantoin therapy, is characterised by dyspnoea, orthopnoea, fever, persistent cough and interstitial pneumonia and/or pulmonary fibrosis. However, fever and eosinophilia are observed more rarely. Improvement is more gradual upon discontinuation of the product. Symptoms of the chronic form, which can occur after approximately 6 months of nitrofurantoin therapy, are those of the subacute form. Associated symptoms and damage are only partially reversible.&nbsp;<br />&nbsp;<br />Gastrointestinal disorders Uncommon: vomiting, abdominal pain and diarrhoea. Rare: pancreatitis. Unknown: nausea and anorexia.&nbsp;<br />&nbsp;<br />Hepatobiliary disorders Rare: hepatic reactions, cholestatic jaundice and chronic active hepatitis including cases of death have been reported. Cholestatic jaundice is normally associated with short treatments (of up to 2 weeks). Chronic active hepatitis occasionally leading to hepatic necrosis is usually associated with long-term treatments (of over 6 months); it can begin insidiously and initially be unnoticed. Treatment must be discontinued at the first sign of hepatotoxicity.&nbsp;<br />&nbsp;<br />Skin and subcutaneous tissue disorders&nbsp;<br />&nbsp;<br />Rare: erythema nodosum and temporary hair loss.&nbsp;<br />&nbsp;<br />Renal and urinary disorders&nbsp;<br />&nbsp;<br />Rare: crystalluria.&nbsp;<br />&nbsp;<br />Reproductive system and breast disorders&nbsp;<br />&nbsp;<br />Rare: reversible disorders of spermatogenesis due to epithelial damage to the convoluted seminiferous tubules.&nbsp;<br />&nbsp;<br />General disorders and administration site conditions Very rare: Outbreaks of sweating, feeling of weakness, globus symptoms.&nbsp;<br />&nbsp;<br />Infections and infestations&nbsp;<br />&nbsp;<br />Unknown: As with other antibiotics, additional infections are possible with fungi or resistant microorganisms such as Pseudomonas.&nbsp;<br />&nbsp;<br />&nbsp;<br />To reports any side effect(s): &nbsp;<br /> Saudi Arabia: &nbsp;<br /> The National Pharmacovigilance and Drug Safety Centre (NPC) &nbsp;Fax: +966-11-205-7662 &nbsp;Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. &nbsp;Toll free phone: 8002490000 &nbsp;E-mail: npc.drug@sfda.gov.sa &nbsp;Website: www.sfda.gov.sa/npc &nbsp;<br />&nbsp;<br />&nbsp;<br />Other GCC States: &nbsp;<br />&nbsp;<br />&nbsp;Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">An overdose can lead to an increase in undesirable effects such as nausea, vomiting, headache and dizziness. In the event of acute intoxication, gastric lavage should be performed. If absorption has already taken place, nitrofurantoin can be removed by haemodialysis, if necessary. Monitoring of blood count, hepatic function tests and pulmonary function is recommended. Fluid intake should be kept high to encourage urination.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">ATC code: J01XE01 Mechanism of action Nitrofurantoin is an antibiotic with activity against most urinary tract pathogens. It acts as a bactericidal agent in the renal tissues and in the urinary tract. The spectrum of sensitive microorganisms includes: Escherichia coli, &nbsp;Enterococcus faecalis, &nbsp;Klebsiella species, &nbsp;Enterobacter species, &nbsp;Staphylococcus species (e.g. S. aureus, S. saprophyticus, S. epidermidis). Citrobacter Species Clinically, the most common urinary pathogens are nitrofurantoin-susceptible.&nbsp;</p><p dir="ltr">Certain strains of Enterobacter and Klebsiella are resistant. Nitrofurantoin is ineffective against most strains of Proteus species or Serratia species, as well as Pseudomonas species. The detailed mechanism of action of nitrofurantoin is not precisely known. Its action is probably based on interference with various bacterial enzyme systems (interference with protein synthesis). At low concentrations, its mode of action is primarily bacteriostatic and, at higher concentrations, it is bactericidal against proliferating and dormant pathogens. Active antibacterial concentrations are reached only in the interior of the efferent urinary tract and not in the blood or other tissues.&nbsp;<br />&nbsp;<br />In vitro sensitivity spectrum Susceptible microorganisms (MIC90 &lt;32 &micro;g/ml) Enterococci, E. coli, Citrobacter spp., Streptococcus group B, Staphylococcus aureus, Staphylococcus epidermidis, Salmonella spp., as well as Bacteroides spp. and Streptococcus pneumoniae, which, however, are rarely a cause of infections in the urinary tract system.&nbsp;<br />&nbsp;<br />Partially or moderately susceptible microorganisms (MIC90 = 32-128 &micro;g/ml) Enterobacter spp., Klebsiella pneumoniae.&nbsp;<br />&nbsp;<br />Resistant microorganisms (MIC90 &gt;128 &micro;g/ml) Pseudomonas aeruginosa, Proteus spp., Pseudomonas cepacia, Providencia spp., Serratia spp., Acinetobacter. It is recommended that a sensitivity test be carried out in infections caused by moderately susceptible microorganisms, so that possible resistance can be excluded.&nbsp;<br />&nbsp;<br />Resistance/Cross-resistance During therapy, resistance develops slowly and gradually. Certain strains of Enterobacter and Klebsiella are resistant, while Acinetobacter, Providencia, Pseudomonas and Serratia are generally always resistant. Cross-resistance with other nitrofurans can occur; however, no cross-resistance with other antibacterial agents has been reported to date.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption Nitrofurantoin is rapidly and almost completely absorbed from the small intestine. The macrocrystalline form is released more slowly, with the result that high initial serum concentrations are avoided and gastric intolerability occurs less frequently than with the usual microcrystalline form. Therapeutically effective serum levels are not achieved with standard doses. After a single 100 mg dose of UvaminTM 100 retard, the mean peak plasma concentration was 460 ng/ml. Peak urinary concentrations were between 13 and 88 ng/ml, which were reached in most cases after 2-6 hours.&nbsp;<br />&nbsp;<br />Distribution The volume of distribution is 0.3-0.7 l/kg and plasma protein binding is about 50-60%. Nitrofurantoin crosses the placenta and is excreted in human milk.&nbsp;<br />&nbsp;<br />Metabolism The substance is metabolised rapidly in the body. About 40-50% is inactivated in the liver by glucuronidation and N-acetylation.&nbsp;<br />&nbsp;<br />Elimination Nitrofurantoin is excreted mainly via the renal route. About 40% of the administered dose appears unchanged in the urine. The remaining 60% is metabolised at various sites including the liver. 16.7% of nitrofurantoin is metabolised by glomerular filtration and 83.3% by tubular secretion. Reabsorption is dependent on the urinary pH. As a weak acid, nitrofurantoin undergoes non-ionic diffusion. With increasing urinary acidity, a significant fraction of the amount excreted proximally is reabsorbed in the distal nephron segments, whilst alkalinisation of the urine results in higher urinary concentrations of&nbsp;nitrofurantoin. However, alkalinisation of the urine for the treatment of urinary tract infections is of little benefit, as the antibacterial efficacy of nitrofurantoin is reduced as a result. People with normal renal function have a serum half-life of only 20 minutes.&nbsp;<br />&nbsp;<br />Kinetics in special patient groups In patients with severely impaired renal function, nitrofurantoin accumulates in the serum with a plasma half-life of up to 1 hour. Nitrofurantoin is contraindicated in patients with a creatinine clearance of less than 60 ml/min due to the expected risk of accumulation and loss of efficacy.&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Mutagenesis Nitrofurantoin induces point mutations in certain types of Salmonella typhimurium and forward mutations in L5178Y mouse lymphoma cells. Nitrofurantoin caused increased sister chromatid staining and chromosome aberrations in CHO cells, but not in human cell cultures. Following administration of nitrofurantoin doses via the feed or injection, results of the Drosophila sex-linked recessive lethal assay were negative. Nitrofurantoin did not cause any hereditary mutations in laboratory rodents.&nbsp;<br />&nbsp;<br />Carcinogenicity Nitrofurantoin led to an increased incidence of tubular adenomas, benign mixed tumours and granulosa cell tumours of the mouse ovary. In one study, in which pregnant female mice were subcutaneously administered 75 mg/kg of nitrofurantoin, papillary adenomas of unknown severity were identified in the F1 generation. An increased incidence of abnormal renal tubular cell neoplasms, osteosarcomas and subcutaneous neoplasms was observed in male rats.&nbsp;<br />&nbsp;<br />Reproductive toxicity An increased malformation rate was observed in animal studies.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Capsule fill: hypromellose, lactose monohydrate, cellulose microcrystalline, purified water.&nbsp;<br />Capsule shell: hard gelatin capsule shell, gelatine, quinoline yellow, titanium dioxide.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30 &ordm;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Uvamin 100 mg retard capsules are packed in PVC/PVDC &ndash; Aluminium blisters, which are packed in carton box. Each pack contains 2 blisters each of 10 capsules.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino Pharma AG, Liesberg, Switzerland 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2018 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>